Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (5164)	8/25/1998 2:47:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

BigKNY3, thank you for the detailed analysis of the data. Ever since the death stats got reported, we PFEers (or at least the longs) have commented on its statistical insignificance in relation to the average death rate for similar demographics. No matter, the Freedom of Information Act enables anyone to make a Freedom of Information request for an update from the FDA on such data every week if they care to (filling in a form and paying a small fee is no sweat), and so we get and will continue to get these "death news reports" regularly. You can be sure that Bloomberg's report would be re-reported ad nauseam by Reuters, Dow Jones/Wall Street Journal, AP, and ALL the national and international newspapers, not to mention all the doomers-and-gloomers in the other threads. The EMEA said Viagra should be available only on prescription, to men with no history of cardiac problems who have undergone a medical examination. Germany, reported earlier to have concerns over the drug following the deaths of six users in the US, is understood to have pushed successfully for more information about contra-indications to be included in the instructions. (Source: the Financial Times article posted earlier by you) Pfizer would likely take a even more cautious stance when marketing Viagra in Europe, which is a wise course to take, IMHO. Hopefully there'll be fewer "death reports" in EU countries. Yesterday's Celebra news should be great for PFE's stock price and the obesity drug news should also be good for at least a point (granted, the obesity drug is still in the early stage of development, but normally traders don't care). Long term holders of PFE should at least take comfort on knowing that Pfizer has a great pipeline and will continue to spend money in R & D in developing other promising new drugs. The obesity drug may yet turn out to be a bigger money maker than Viagra 5 or 6 years down the road. Anthony